Abiomed (ABMD) Posts Q3 Adj-EPS of $0.70

Abiomed (NASDAQ: ABMD) reported Q3 EPS of $0.70, which may not compare to the analyst estimate of $0.51. Revenue for the quarter came in at $154 million versus the consensus estimate of $148.54 million.

Third quarter fiscal 2018 GAAP net income was $13.4 million, or $0.29 per diluted share. Third quarter fiscal 2018 adjusted* net income before the recently enacted Tax Reform Act was $32.2 million, or $0.70 per diluted share, compared to $15.4 million or $0.34 per diluted share for the prior year period. Third quarter fiscal 2018 adjusted* net income included income tax expense adjustments of approximately $18.8 million, or $0.41 per diluted share due primarily to the recently enacted Tax Reform Act and excess tax benefits on employee share-based compensation awards, which were not applicable in the prior year period.

For earnings history and earnings-related data on Abiomed (ABMD) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance